Story thread · 5 reports / 5 sources

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

medcitynews.com · 12dShare

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one. The post Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial appeared first on MedCity News .

First report: Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential — thestar.com, 12d